TSRL, Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies

TSRL, Inc. is a preclinical accelerator that collaborates with academic researchers and other small businesses on the translation of their therapeutic concepts into clinical drug candidates. We are focused on developing the first pain-free transdermal microneedle (MN) patch, TSR-066, to provide a 5-day treatment course of zanamivir (ZAN) for the flu. Relenza®(ZAN), a difficult to use dry powder inhaler, requires twice a day inhalation and is contraindicated in patients with pre-existing lung conditions, a patient segment particularly vulnerable to flu infections and complications. Other oral competitors are notoriously plagued by resistant virus emergence. TSR-066 is a swellable microneedle drug-device combination product that is self-applied once by the patient, and delivers ZAN continuously over five days. The drug has years of human safety, and a 505(b)2 regulatory pathway will be available for the development and registration of TSR-066.


 


TSRL, Inc. is presenting as part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Michigan
Company HQ Country:
United States
Year Founded:
1986
Main Therapeutic Focus:
Lead Product in Development:
TSR-066 (drug/device transdermal patch for flu)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
photo
CEO
TSRL, Inc.